Brief: HBM Holdings Says Positive Results From Phase I Trial For HBM4003
13/09/2021 07:09
Sept 13 (Reuters) - Hbm Holdings Ltd 2142.HK :
* POSITIVE RESULTS FROM PHASE I DOSE ESCALATION CLINICAL
TRIAL FOR
HBM4003
Source text for Eikon: ID:nHKSlwkVm
Further company coverage: 2142.HK
(Reporting by Harshita Swaminathan)
((Harshita.Swaminathan@thomsonreuters.com;))
Recent news on HBM Holdings
See all newsBrief: HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis
HBM climbs on development of AI biology foundation model
Brief: HBM Holdings' Unit Develops World's First Language Model For Fully Human Heavy-Chain-Only Antibodies
Brief: Hbm Holdings Says Solstice Oncology Launches Series A Financing Round
HK-listed HBM climbs on initiating next phase of asthma drug study